JS
Jonathan R. Strosberg
Elite in Pancreatic Cancer
Check Dr. Jonathan R. Strosberg's experience treating your condition:
About Dr. Jonathan R. Strosberg

Jonathan Strosberg is a Hematologist Oncology specialist and an Oncologist in Tampa, Florida. Strosberg has been practicing medicine for over 24 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Familial Pancreatic Cancer, and Liver Embolization. He is licensed to treat patients in Florida. Strosberg is currently accepting new patients.

His clinical research consists of co-authoring 186 peer reviewed articles and participating in 21 clinical trials in the past 15 years. In particular, he has co-authored 59 articles and participated in 5 clinical trials in the study of Pancreatic Cancer.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Jonathan R. Strosberg it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
12902 Usf Magnolia Dr, Tampa, FL 33612
Other Locations
4101 Jim Walter Blvd, Tampa, FL 33607
Background & Education
Graduate Institution
Js Weill Medical College, Cornell University, 1999
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
AdventHealth Orlando
Moffitt Cancer Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


21 Clinical Trials

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
HORMONET: Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Phase II Study of Axitinib in Advanced Carcinoid Tumors
Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
A Multicenter Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome
A Phase 2 Open-Label Study of RO4929097 in Metastatic Colorectal Cancer
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors
View 16 Less Clinical Trials -

185 Total Publications

A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Elite
Distinguished
Distinguished